AREV Life Sciences Global Corp.
AREVF · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.07 | 0.20 | 0.06 | 0.01 |
| FCF Yield | -11.03% | -15.63% | -10.02% | -13.67% |
| EV / EBITDA | -2.55 | -11.78 | -10.46 | -0.97 |
| Quality | ||||
| ROIC | 150.34% | 8,427.63% | -477.12% | -6,385.95% |
| Gross Margin | 59.33% | 72.60% | 100.00% | 66.33% |
| Cash Conversion Ratio | 0.20 | 1.48 | 0.02 | 0.04 |
| Growth | ||||
| Revenue 3-Year CAGR | -36.36% | 9.41% | – | – |
| Free Cash Flow Growth | 75.29% | -208.96% | -45.87% | 74.76% |
| Safety | ||||
| Net Debt / EBITDA | -0.02 | 0.10 | -0.88 | -0.18 |
| Interest Coverage | -228.08 | -32.38 | -7.69 | -41.33 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 3.50 | 0.00 | 0.00 |
| Cash Conversion Cycle | -14,357.51 | -2,196.46 | 50.64 | -1,701.87 |